Ann: FDA Clears Cynata IND for Phase 2 Trial in GvHD, page-11

Fate also got a nice little partnership deal with Johnson and Johnson in April 2020, that along with its FDA IND clearance of its IPSC allogeneic chimeric antigen receptor (CAR) T-cell therapy in July 2020, sent the stock to sixfold highs. Lets hope CYP garners some similar big Pharma interest. The IPSC field is saturated as you point out, particularly in CAR T-cell therapies.

That this is the only MSc IND is a very big deal and sure to capture big Pharma attention. At $59 million mkt cap, Novartis or someone might trim the stationary expenses by 3% or something and pick it up with change to spare!!